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A B S T R A C T
Capsular contracture is a signiﬁcant diﬃculty where implants are used in both breast augmentation and
breast reconstruction surgery. This report reviews the published literature focusing on factors and tech-
niques that reduce the incidence of this complication, as well as evaluating the available treatment options
for patients who have developed a contracture.
A search of the MEDLINE database for clinical studies involving the understanding, diagnosis and man-
agement of capsular contracture was performed, with 106 articles deemed relevant for this review. Our
search criteria included observational studies as we wish to discuss and highlight the areas of this con-
dition that have been investigated, and unfortunately there is limited clinical evidence in regard to high
quality trials in this ﬁeld.
Risk factors for capsular contracture are multi-factorial, and all surgeons should aim to minimise these
as much as possible both intra- and peri-operatively. However, in high risk patients it is not achievable
to completely remove these elements. When capsular contracture does develop, there are currently only
a limited number of surgical options including capsulotomy, capsulectomy with or without re-
implantation, or reconstruction with autologous tissue. These procedures, as well as the original implant
surgery, ought to be discussed with patients on an individual basis, taking into account their personal
needs and expectations.
The future of this complication may lie in the development of pharmaceutical interventions, and recent
studies have shown promising results. Although this ﬁeld requires more research, the effectiveness of
some new pharmaceutical approaches, to provide alternative non-surgical options for patients with cap-
sular contracture, can only aid both patients and the breast surgeon.
© 2016 The Authors. Published by Elsevier Ltd on behalf of Surgical Associates Ltd. This is an open
access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
1. Introduction
Capsular contracture is a complication of breast augmentation
which continues to reduce both surgeon and patient satisfactionwith
the end appearance of the breast. It has beenwell documented across
the literature although still remains an enigma in both its forma-
tion as well as in regard to reducing its presentation.
There are numerous available systematic reviews and hun-
dreds of studies on various topics within capsular contracture. Our
objective for this paper is to review and present the current un-
derstanding of capsular contracture in breast augmentation that is
available in the literature. We can ﬁnd no single paper which
summarises its aetiology, initial interventions to reduce its occur-
rence and later management.
2. Methodology
We reviewed the literature, searching the EMBASE andMEDLINE
databases from inception to January 2014 with the following search
term used:
capsular[All Fields] AND (“contracture”[MeSH Terms] OR
“contracture”[All Fields]) AND (“breast”[MeSH Terms] OR “breast”[All
Fields])
This as well as pertinent linked ‘related citations’ were reviewed.
We decided to include all studies, including observational reports
so as to provide an understanding of current methodology and areas
of interest in this condition. There is a recent systematic review by
Araco et al [1] which showed little high quality studies, and we did
not wish to repeat this study.
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Exclusion criteria included those with abstracts not written in
English and communication letters.
Using the search terms above, 803 articles were found. Thesewere
reviewed in regard to title and abstract using a priori criteria re-
sulting in 150 articles being reviewed in more detail. Of these, 106
were found to be relevant and are referenced below. The follow-
ing aim to summarise the ﬁndings in the papers reviewed.
3. Capsular contracture – A review of the literature
3.1. Introduction
Patients who undergo breast augmentation or reconstructionwith
implants are largely satisﬁed with the resulting breast appearance
[2,3].
Despite this, it is still the surgeon’s duty to accurately council
and educate the patient about the potential complications (both
those that can occur, and those that are believed by the patient to
be possible, from the surgery) [3–23] and how these may lead to
an undesirable result. These complications include haematoma, scar-
ring (both hypertrophic and keloid), infection, seroma, necrosis,
breast asymmetry and most importantly, the commonest compli-
cation seen, capsular contracture [24–28].
Capsular contracture develops due to the fact that the implant
is too large to be successfully phagocytised by the body, as would
happen with a much smaller imbedded foreign body. Likewise, sil-
icone is too inert to cause a toxic reaction, as it has no active bindings
sites [29]. Instead, a ﬁbrous capsule, made of myoﬁbrils and colla-
gen, surrounds the foreign implant. Normally it does not exceed
the 1 mm [30] – 1.5 mm [31] thickness. This capsule formation is
described as a part of the normal healing process, and some
studies suggested it might even help to keep the implant in situ
[16,32].
However, when this capsule thickens and the implants dimen-
sions are altered, then the condition is described as capsular
contracture.
At best the capsule compromises the aesthetic appearance of the
breast; at worst it causes the breast to feel ﬁrm, even hard and painful
[16,29].
As the capsule contracts around the implant it does so with a
centripetal force, changing the natural implant shape to a sphere,
a shape which has the smallest surface area to volume ratio [20].
This leads to the appearance of spherical breasts, deﬁning capsu-
lar contracture, a ﬁnding similar to the unnatural effects of the push-
up bra [20]. Likewise, the pressure on the walled-off implant causes
it to feel harder to touch then when no capsule is present.
The incidence of capsular contracture is diﬃcult to pinpoint. The
use of new techniques has meant that some surgeons achieve con-
sistently low contracture rates [20].
Certain factors such as the indication for surgery will increase
one’s risk, and the incidence in these patient groups will naturally
be higher [27].
Capsular contracture is commonly graded using the Baker Clas-
siﬁcation [6,33]. This has been revised to take into account those
patients who have had prosthetic breast reconstruction, rather than
solely patients with ﬁrm breasts after augmentation mamma-
plasty, as the original classiﬁcation described. Typically patients
graded Class III or IV will require intervention.
Although a range from zero to 50% has been noted [34], a more
realistic incidence for capsular contracture, would be between 8%
and 15% [35].
There is some discrepancy as to agreement over when capsu-
lar contracture is likely to develop and present. Some studies have
noted its appearance as early as two years after surgery [3], while
others have documented development at ﬁve years [34]. Studies
suggesting presentation within a year support the subclinical
infection pathway described below, as well as the relationship to
surgical technique, drain placement and other short-term compli-
cations [3].
Presentations later than this are possibly caused by a second-
ary infection from systemic bacteraemia, elastomer degradation or
ﬁller bleeds [27], or the chronic effect of the implant on surround-
ing tissues [3].
4. Capsular contracture: Diagnosis and classiﬁcation
4.1. Diagnosis
4.1.1. Clinical
Capsular contracture may initially present with mild breast in-
duration. With progressive increase of capsule thickness, the breast
becomes ﬁrmer. It may progress and eventually shrink the breast
in such a way that it totally distorts the breast shape. It may result
in a range of symptoms, varying from local tenderness to severe pain
[1].
4.1.2. Radiological
Mammography. Mammography is ideal for breast parenchy-
mal evaluation and obvious extracapsular silicone implant rupture.
It fails, however, to consistently detect intracapsular implant rupture
[36,37].
Mammography can be useful in evaluating the breast with
minimal tomoderate capsular contracture.With severe capsular con-
tracture, mammography has a very limited use in assessing the breast
[38].
Ultrasound scan [39–45]. The diagnostic accuracy of ultra-
sound in the hands of a skilled radiologist has a very high sensitivity
[39–42]. However, due to the steep learning curve, the absence of
a panoramic view and the high operator dependence, there is much
debate about the usefulness of this investigative tool.
MAGNETIC RESONANCE IMAGING. Numerous studies have shown that MRI
is the most reliable test [37,46–48], and it has been proven to also
be the most accurate, as well as being non-operator dependant
[49–51].
MRI has therefore been crowned the ‘gold standard’ [52] for
imaging implants. In the USA, the Food and Drug Administration
guidelines recommendMRI-implant evaluation at 3 years after breast
augmentation and every 2 years thereafter [53].
4.2. Classiﬁcation of capsular contracture
As above, Bakers classiﬁcation is commonly used as the stan-
dard for commenting on the amount of breast contracture evident.
The basis of this classiﬁcation is around patient perceived ﬁrm-
ness or pain in the breast, the clinically palpable implant and the
implants visibility. Grade IV is universally deemed an indication for
removal of the implant, although earlier classes should be re-
viewed on a patient by patient basis. The original classiﬁcation
described by Baker in 1978 [33], aimed at the augmented breast,
was expanded to include reconstructed breasts in 1995 by Spear,
with the division of I into IA and IB [6]. IA still described an aug-
mented or reconstructed breast which appeared absolutely natural,
but IB described a palpable implant on examination. These descrip-
tions are summarized in Table 1. Gylbert made further comments
on the palpable deformity in 1989 [54], and multiple other descrip-
tions have been attempted over the years [55], although the Baker
classiﬁcation remains to both be popular and the most practical
method of assessing breast ﬁrmness [6].
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5. Capsular contracture: Possible aetiological background
theories and reducing their impact
The aetiology of capsular contracture is not fully understood, and
probably multifactorial.
Many theories have been suggested including that an inﬂam-
matory process secondary to a subclinical infection, particularly in
the asymptomatic patient, leads to scar formation. Another thought
is that it is of an immunological nature [27].
This second theory arose from studies that illustrated eleva-
tion of serum ﬁbrosis indices and other humoral factors, which
directly correlate to the degree of contracture [10,56].
Other theories that have been suggested and explored include
the haematoma formation, foreign body reaction and myoﬁbroblast
activation theories [5,44,57].
It has been suggested that implants with a textured surface have
been shown to reduce or delay the rates of capsular contracture for-
mation [2,58–63] and shown to be conclusive certainly for
subglandular breast augmentation in the meta-analysis by Wong
et al [26]. This study however stated that further investigationmight
be needed to see if this is maintained long-term, and to exclude only
a delay in the capsular contracture.
In the early nineties, Hakelius and Ohlsen also conﬁrmed that
textured implants reduced the development of capsular contrac-
ture [64].
Much more recently, in 2006, Barnsley et al. published a meta-
analysis highlighting that textured implants reduced the risk ﬁve-
fold [63]. However, some papers report no advantage [65,66].
When analysing the relationship between silicone and capsu-
lar contracture, several studies have been undertaken, with varying
results. One study showed no difference between silicone and saline
implants in an experiment involving rabbitsmodels [67], while others
have demonstrated a deﬁnitive association between silicone and
capsule formation when compared [68–70].
In the late 1970s, Cairns and de Villiers [71] identiﬁed capsular
contracture in 90.7% of the implanted silicone prosthetics in their
cohort, after a 4 year period. They described them resulting in a con-
tracture, classed as a Baker grade of III, which is similar to ﬁndings
since reported by Reiffel et al. [72] and Gylbert et al [73].
Gasperoni et al. [74] found a capsular contracture rate of 3.3%
when polyurethane-coated implants were utilized and only a few
of the contractures were found to be clinically signiﬁcant. The theo-
ries proposed, regarding why polyurethane-covered implants may
prevent or prolong the onset of capsular contracture, include: ﬁrst,
collagen ﬁbrils are arranged randomly into ‘sponge’ spaces, rather
than parallel [60]; and second, punctures to the implant are less likely
to result in a rupture, leading to silicone leak from the implant [75].
It has also been suggested that as the polyurethrane degrades
through phagocytosis that there is no alignment of scar (capsular)
tissue.
Placement of the implant may be either subglandular or
submuscular [28]. Literature tends to favour the submuscular and
subfascial placement for reducing the incidence of capsular con-
tracture [65]. Hendricks reported no Baker III or IV with submuscular
placement [76]. With subfascial placement Ventura and Marcello
[77] found only 2% of patients were graded Baker II. Finally, Gutowski
et al. published data reporting that the subglandular position in-
creased risk eight-fold for developing capsular contracture [78]. This
said, some have found no signiﬁcant association [79].
When placed under the muscle, the clinical detection of capsu-
lar contracture is thought to be less, and the overlying muscles
(pectoralis major, external oblique, rectus sheath and serratus an-
terior muscle fascia) act as a barrier to the glandular tissue [76]. The
muscle boundary also ‘massages’ the implant when themuscles con-
tract, favouring anatomical and physiological organisation of the
capsule collagen ﬁbres. However, submuscular placement is not pref-
erable for patients who participate actively in sports [28].
The breast ducts connect the deep tissue with the skin surface
so it is not surprising that the breasts contain bacteria commonly
seen in the natural skin ﬂora. Placing the implant into the
submuscular limits the direct contact with the glandular tissue and
thus minimises bacterial contamination [80].
Bacterial infection is thought to play a part in the development
of capsular contracture. Contamination with Staphylococcus
epidermidis with miniature implants using sixteen rabbits showed
that contaminated implants had uniformly ﬁrmer consistency. His-
tology showed ﬁbrous capsules with abundant collagen formation
and that they were two to three times thicker than the (saline)
control [81].
Although S. epidermidis is well documented, a variety of organ-
isms have been isolated as causative [82,83] and a broad spectrum
antibiotic approach should be initially implemented. Rates of cap-
sular contracture have been reducedwith the use of a triple antibiotic
breast irrigation technique (often cefazolin, gentamycin and baci-
tracin). This has been recommended to improve clinical outcome
and for its cost-effectiveness by several papers [27,34].
The longer the implant has been in place, the higher the risk of
developing a contracture, with a direct correlation assumed to exist
[61]. Araco et al. support Handel’s hypothesis of capsular contrac-
ture as a chronic and progressive complication [34]. In a study
evaluating treatment options, the ‘watch andwait approach’ showed
that the capsular contracture worsened [16]. Other studies have
proven that increased implant duration has shown capsules to be
signiﬁcantly thicker [30].
Numerous intra-operative techniques have been described to
reduce contracture rates. Antibacterial breast pocket irrigation, intra-
operative 10% povidone–iodine washes [84,85], thorough
haemostasis, talc-free gloves when handling the implant and peri-
operative antibiotics have been suggested as being important in
optimising outcomes of breast augmentation [26].
Lower rates of capsular contracture are favoured by an
inframammary incision (0.59%) rather than the peri-areolar inci-
sion (9.5%). The likely reason for this is again the bacterial
contamination pathway, with the assumption of taking a deeper
route through the breast tissue and bypassing the ducts near the
nipple-areola complex that harbour higher quantities of bacteria
by their nature of being closest to the skin surface [86].
6. Capsular contracture: Conservative and surgical
management
6.1. Medical
Pirfenidone (PFD) has anti-inﬂammatory and antiﬁbrotic char-
acteristics. In a study in 2006 [87], the administration of PFD
immediately after mammary implantation in a series of 10 rats, and
continued for eight weeks reduced inﬂammation, contracture and
capsule thickness when compared to the control. The total content
of collagen in the PFD group was 50% less than the control. Despite
a small sample, the results were encouraging to suggest a larger,
human study should be undertaken.
Table 1
Baker Classiﬁcation of breast contracture [6,33].
Baker
Class
Breast
ﬁrmness/pain
Implant Implant visibility
IA Soft Non palpable Non visible
IB Soft Palpable Non visible
II Minimal Palpable Non visible
III Moderate Easily palpable Distortion visible
IV Severe Hard, tender, cold Distortion may be marked
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Leukotriene receptor antagonists (LTRA) may present a new non-
surgical approach for the management of capsular contracture
[88–92].
Zaﬁrlukast (Accolate) has been used in the prevention and long
term treatment of asthma. It is well tolerated although reported side
effects include headache and nausea.
It was initially believed that this anti-inﬂammatory agent could
perhaps be used in the treatment of capsular contracture after a
patient presented with Baker grade III, two months after a primary
breast augmentation. A dramatic improvement was seen using this
treatment, and at threemonths the patient was re-classiﬁed as Baker
grade I.
The anti-inﬂammatory properties target cellular-mediated pro-
liferation without the unwanted effect of a generalised
immunosuppression. A statistically signiﬁcant difference of capsu-
lar contracture rate (4% down to 1%) was noted when Zaﬁrlukast
was introduced. It appears to be most effective in the early stages
(less than six months) and prophylactically in high risk patients.
The longevity of these impressive results once patients are off,
the therapy is yet to be established.
Montelukast has also been found to be effective, but not to the
same extent [88].
In one study, using 40 rat models, the collagen ﬁbres and ﬁbro-
blast layer were reduced in the Zaﬁrlukast-treated group compared
to the control. The study conﬁrmed effectiveness in preventing ﬁ-
brosis and in reducing the extent of collagen reaction when a capsule
has been formed [89].
A prospective study of 120 females (216 prostheses) showed that
Zaﬁrlukast may be effective in reducing pain and breast capsule dis-
tortion in long standing contracture for over a year [90].
However despite this promising evidence, hepatic failure is a rare
but very serious associated complication. Liver function tests may
be appropriate in patients treated with Zaﬁrlukast [91,92]. Mainly
for this reason, Zaﬁrlukast is at present not indicated for breast
implant surgery, until the full extent of the side effects and effec-
tiveness are understood. Randomised clinical trials are currently
underway [28].
Many papers [93–95] have suggested the use of triamcinolone
injections. A recent study in Italy, published in 2011, demon-
strated that ultrasound guided injection of 40 mg of triamcinolone
acetonide, in the peri-implant area of breasts affected by Baker grade
IV capsular contracture, is effective in reducing capsular thickness
and patients’ discomfort even in the patient who has undergone ad-
juvant chemo-radiation therapy for breast cancer [96].
Ultrasound guided injection allows safe delivery of steroids into
the small space around the implant after breast augmentation or
reconstruction [96].
6.2. Manipulation
Closed capsulotomy describes a technique where the breast is
ﬁrmly grasped and manually compressed to rupture the underly-
ing periprosthetic scar tissue [28]. This procedure has initially a good
outcome (100% ‘better’ or ‘same’), however these effects are short-
lived, meaning the procedure has to be repeated numerous times
(58% of breasts had the procedure more than once) [16].
The complications associated with closed capsulotomies
(haematoma, shell rupture with Silicone leak, implant
pseudoherniation) are not acceptable by today’s standards, and this
procedure is not advised in light of this and the limited short-
term beneﬁts.
6.3. Ultrasound [97–99]
A study conducted in 2002, in Spain, which looked at the use
of external ultrasound to both treat and prevent the formation of
capsular contracture, showed promising results [98]. J. Planas, the
leading clinician, claimed success rates of up to 97% in improving
the clinical ﬁndings, ‘by at least one Baker degree’. To achieve this,
anything between 2 to 16 sessions, of ultrasound application were
needed, and the best results were seen with subglandular implants.
6.4. Surgery
Capsular contracture is seen less often when the procedure is
primary augmentation [61]. The risk increases if the surgery is a
revisional intervention; even more so in breast reconstruction [3].
With breast reconstruction patients, theymay have pre- and post-
operative exposure to chemotherapy and or radiotherapy. These
adjuvant therapies are known to increase the rates of subclinical
infection and subsequently enhance the natural ﬁbrosis of tissues
[39]. Patients who will, or have post mastectomy radiation have
optimised results with a delayed autologous tissue reconstruction
after therapy [100].
Surgical approaches (capsulotomy or capsulectomy) are often re-
served for patients scoring Baker III or IV [1].
Open capsulotomy describes a surgical approach with usually
circumferential and longitudinal cuts made into the ﬁbrous capsule
to end the distortion of the implant. The capsule is not removed,
but the breasts are softened. This is the preferred, less extensive tech-
nique for submuscular cases [1,28].
In submuscular patients, the posterior wall of the capsule lies
directly on the ribs and attaches to the intercostals muscles.
Capsulotomy therefore reduces the risks of the more complicated
capsulectomy which includes haematoma and pneumothorax
[101,102].
After the removal of saline implants, the capsule has been shown
to contract and reduce, folding over the ﬁrst couple of months and
virtually disappearing after a year. Capsulotomy may be the pre-
ferred treatment for patients with saline implants [1].
Complete capsulectomy removes the anterior and posterior scar
tissue. If no implants are to be re-inserted in the space, it is left to
heal. Capsulectomy has increased risks when involving submuscular
implants, on account of the capsule resting on the intercostal
muscles. This is based on the theory of a bioﬁlm, and so, removal
of all bacteria harbouring capsule and prosthesis is needed [103,104].
Evidence suggests that calcium can accumulate in a capsule left
behind and interfere with routine screening mammograms. Cap-
sules from silicone implants have also been shown to produce further
contractures even long after the implants have been removed. Since
the capsule is removed with this procedure these complications are
avoided in capsulectomy [1].
Implant removal alone may solve the problem but may not
however give an acceptable cosmetic result to the patient if there
is a lot of skin excess or great amount of ptosis in the empty breasts.
In this situation, a mastopexy may address this. Alternatively re-
implantation can be considered, as can reconstruction with
autologous tissue, with both options discussed below.
Re-augmentation into a different plane is preferred as reoccur-
rence risk is very high for reinsertion into the same position [1].
If the original implant is in the subglandular plane, then re-
implantation is preferred submuscularly. This position also facilitates
mammographic investigation, ensures adequate tissue coverage, and
avoidance of contact between the new implants and the inﬂamed
glandular tissue [1,28].
If the ﬁrst placement of implants was submuscularly, capsulotomy
is indicated and the implant may be replaced in this position. In a
lot of cases, there is not enough tissue to cover the implant, and
rippling risk is high [28]. However, one study suggests an alterna-
tive. On 36 patients with subpectoral implants requesting re-
augmentation the implant (s) were removed, modiﬁed capsulectomy
performed, the pectoralis major muscle re-suspended to the chest
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wall. They then underwent re-implantation in the subglandular po-
sition for re-augmentation. This has been successfully performed
on patients with capsular contracture [105].
The individual needs of the patient need to bemet. Strictly speak-
ing, the only way of treating the capsular contracture and preventing
re-occurrence is to remove the implant, without implant replace-
ment [28].
Some patients who have had repeated capsulectomies and
implant exchanges have found pleasing results at 5 years accord-
ing to Gurunluoglu et al. when autologous tissue is used to
reconstruct the breast [106]. Here, a total of 14 ﬂaps were created
to maintain breast volume and aesthetic appearance where new im-
plants were not desired.
These included TRAMﬂaps, DIEP ﬂaps and SIEA ﬂaps. Thismethod
of reconstruction produced satisfactory results and is an optionworth
considering in the patient who gains no improvement from themore
simple surgical techniques.
6.5. Conclusion
It should be noted that there is little in the way of controlled
trials in regard to the prevention and/or management in capsular
contracture. Capsular contracture has complicated breast augmen-
tation from day one, and studies that describe their experience in
this ﬁeld are often diverse and multifactorial, making it diﬃcult to
suitably compare or analyse speciﬁc treatments. It is for this reason
that a true systematic review is often limited in its conclusions, and
hence our decision to present a description of current theories and
techniques rather than a ‘cure’ for this complication.
Capsular contracture can be a very distressing complication of
breast augmentation with prosthetic implants leaving a patient with
spherical, hard, painful breasts. Modern techniques have dramat-
ically reduced the incidence and prevention is always better than
cure, and these are shown in Table 2.
Although rates of capsular contracture have dropped consider-
ably over the recent decades, the management options for patients
who are in higher risk groups are important. The patient always has
the option of ‘do nothing’; however, this is unfavourable, patients
typically ﬁnd no relief or that their condition worsens [5].
This is important, as at present, there are limited surgical options
for patients with capsular contracture. It may be cured by removal
of the implants; this however, is unlikely to leave satisfactory aes-
thetic result with an empty ptotic breast.
Reconstruction is possible with autologous tissue in patients
willing to have further extensive surgery. However patients wanting
replacement with implants are less likely to have such pleasing
results with re-implantation (especially into the same plane) with
a high risk of reoccurrence. More research needs to be done to look
at the long-term effects of Pirfenidone and Leukotriene receptor an-
tagonists to see if these are safe and effective pharmaceutical
treatments.
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